Zydus Cadila gets USFDA nod for sclerosis drug
New Delhi: Drug firm Zydus Cadila said it has received tentative nod from the US health regulator to market Fingolimod capsules used for treatment of multiple sclerosis.
"The company has received tentative approval from the United States Food and Drug Administration (USFDA) to market Fingolimod capsules 0.5 mg," Cadila Healthcare said in a filing to BSE.
The drug will be produced at the groups formulations manufacturing facility at pharma SEZ in Ahmedabad, it added.
The product is mainly used for treating multiple sclerosis, Cadila said.
The group now has over 120 approvals and has so far filed more than 300 Abbreviated New Drug Applications (ANDAs), it added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd